{"id":336046,"date":"2019-07-03T02:00:00","date_gmt":"2019-07-03T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/the-clinical-utility-of-pcsk-9-inhibitors\/"},"modified":"2019-07-03T02:00:00","modified_gmt":"2019-07-03T00:00:00","slug":"the-clinical-utility-of-pcsk-9-inhibitors","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/the-clinical-utility-of-pcsk-9-inhibitors\/","title":{"rendered":"The clinical utility of PCSK-9 inhibitors."},"content":{"rendered":"<p><strong>High LDL cholesterol levels are a risk for the development of atherosclerosis. What are the clinical benefits of PCSK-9 inhibitors for cholesterol lowering?<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>At birth, LDL cholesterol concentrations are less than 50 mg\/dl and then increase into adulthood. Values of 125 mg\/dl are then not uncommon. However, very low LDL cholesterol levels reduce &#8211; according to current information &#8211; the risk of heart attack and stroke by one third. Possibilities to lower the levels exist by inhibiting HMG-CoA reductase using statins, cholesterol absorption using Ezetimibe or increasing LDL degradation using PCSK-9 inhibitors, as Prof. Franz, MD. R. Eberli, Zurich, pointed out. The latter have already proven their effectiveness in several studies. &#8220;PCSK-9 inhibitors lower LDL cholesterol by 60%,&#8221; the expert reported. They also score well in terms of safety: There were no indications of muscular or neurocognitive disorders. Antibodies are very rare and allergic reactions occur only occasionally.<\/p>\n<p>But what about the clinical benefit of the new therapy regime? The major endpoint studies FOURIER and ODYSSEY mainly demonstrated a reduction in myocardial infarction rate (1.9% and 1.0%, respectively) and a reduction in cardiovascular events (2% and 1.6%, respectively). In contrast, the risk of cardiovascular mortality and all-cause mortality were not improved. &#8220;PCSK-9 inhibitors can be used in primary and secondary prevention to reduce cardiovascular events, within the limitation given by the FOPH,&#8221; Eberli concluded.<\/p>\n<p><em>Source: Zurich Review Course in Clinical Cardiology.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>CARDIOVASC 2019; 18(3): 38 (published 7\/6\/19, ahead of print).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>High LDL cholesterol levels are a risk for the development of atherosclerosis. What are the clinical benefits of PCSK-9 inhibitors for cholesterol lowering?<\/p>\n","protected":false},"author":7,"featured_media":89751,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"LDL cholesterol reduction","footnotes":""},"category":[11359,11513,11548,11503],"tags":[28533,17948,28536],"powerkit_post_featured":[],"class_list":["post-336046","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiology","category-congress-reports","category-rx-en","category-studies","tag-arteriosclerosis-en","tag-ldl-cholesterol","tag-pcsk-9-inhibitors","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-20 15:02:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":336057,"slug":"les-avantages-cliniques-des-inhibiteurs-de-pcsk-9","post_title":"Les avantages cliniques des inhibiteurs de PCSK-9","href":"https:\/\/medizinonline.com\/fr\/les-avantages-cliniques-des-inhibiteurs-de-pcsk-9\/"},"it_IT":{"locale":"it_IT","id":336065,"slug":"il-beneficio-clinico-degli-inibitori-della-pcsk-9","post_title":"Il beneficio clinico degli inibitori della PCSK-9","href":"https:\/\/medizinonline.com\/it\/il-beneficio-clinico-degli-inibitori-della-pcsk-9\/"},"pt_PT":{"locale":"pt_PT","id":336067,"slug":"o-beneficio-clinico-dos-inibidores-pcsk-9","post_title":"O benef\u00edcio cl\u00ednico dos inibidores PCSK-9","href":"https:\/\/medizinonline.com\/pt-pt\/o-beneficio-clinico-dos-inibidores-pcsk-9\/"},"es_ES":{"locale":"es_ES","id":336024,"slug":"el-beneficio-clinico-de-los-inhibidores-de-pcsk-9","post_title":"El beneficio cl\u00ednico de los inhibidores de PCSK-9","href":"https:\/\/medizinonline.com\/es\/el-beneficio-clinico-de-los-inhibidores-de-pcsk-9\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/336046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=336046"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/336046\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/89751"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=336046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=336046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=336046"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=336046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}